CTSO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.38M

+2.74%

-0.047

-66.66%

9.69M

+11%

-0.040

+100%

10.60M

+10.2%

-0.035

-216.67%

Estimates Revision

The market is revising Downward the revenue expectations for Cytosorbents Corporation (CTSO) for FY2025, with the revenue forecasts being adjusted by -0.83% over the past three months. During the same period, the stock price has changed by -28.03%.

Revenue Estimates for FY2025

Revise Downward

-0.83%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-28.03%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CTSO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTSO is 0.75 USD with a low forecast of 0.75 USD and a high forecast of 0.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

0.75

Averages

0.75

High

0.75

Current: 0.000

Low

0.75

Averages

0.75

High

0.75

H.C. Wainwright

Sean Lee

Neutral

downgrade

2025-11-14

Reason

H.C. Wainwright

Sean Lee

Price Target

2025-11-14

downgrade

Neutral

Reason

H.C. Wainwright analyst Sean Lee lowered the firm's price target on CytoSorbents to 75c from $1 and keeps a Neutral rating on the shares. The firm reduced estimates to reflect to the "continued drag" on the company's Germany revenues.

HC Wainwright & Co.

Sean Lee

Hold

Reiterates

2025-04-03

Reason

HC Wainwright & Co.

Sean Lee

Price Target

2025-04-03

Reiterates

Hold

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-04-01

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-01-13

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-01-13

Maintains

Strong Buy

Reason

D. Boral Capital says CytoSorbents reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The company also demonstrated a significant gross margin rebound to around 70%, underscoring operational resilience and efficiency improvements, the analyst tells investors in a research note. D. Boral believes the results highlight CytoSorbents' strong execution and the growing demand for CytoSorb, its flagship product. The firm keeps a Buy rating on the shares with a $10 price target.

Valuation Metrics

The current forward P/E ratio for Cytosorbents Corp (CTSO.O) is -4.14, compared to its 5-year average forward P/E of -10.37. For a more detailed relative valuation and DCF analysis to assess Cytosorbents Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.37

Current PE

-4.14

Overvalued PE

4.04

Undervalued PE

-24.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-80.20

Current EV/EBITDA

-15.72

Overvalued EV/EBITDA

221.00

Undervalued EV/EBITDA

-381.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.10

Current PS

1.01

Overvalued PS

5.49

Undervalued PS

0.70

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CTSO News & Events

Events Timeline

No data

News

9.5

2025-12-10PRnewswire

CytoSorbents Reports $37M in Q3 Sales; CEO to Join Virtual Discussion

1.0

2025-11-17PRnewswire

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

4.0

2025-11-15NASDAQ.COM

HC Wainwright & Co. Upholds Neutral Rating for Cytosorbents (CTSO)

People Also Watch

Frequently Asked Questions

What is Cytosorbents Corp (CTSO) stock price today?

The current price of CTSO is 0.671 USD — it has decreased -0.3 % in the last trading day.

What is Cytosorbents Corp (CTSO)'s business?

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

What is the price predicton of CTSO Stock?

What is Cytosorbents Corp (CTSO)'s revenue for the last quarter?

Cytosorbents Corp revenue for the last quarter amounts to 9.49M USD, increased 10.12 % YoY.

What is Cytosorbents Corp (CTSO)'s earnings per share (EPS) for the last quarter?

Cytosorbents Corp. EPS for the last quarter amounts to -0.05 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for Cytosorbents Corp (CTSO)'s fundamentals?

How many employees does Cytosorbents Corp (CTSO). have?

Cytosorbents Corp (CTSO) has 149 emplpoyees as of January 10 2026.

What is Cytosorbents Corp (CTSO) market cap?

Today CTSO has the market capitalization of 42.14M USD.